These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 24164599)

  • 1. Discovery of the first M5-selective and CNS penetrant negative allosteric modulator (NAM) of a muscarinic acetylcholine receptor: (S)-9b-(4-chlorophenyl)-1-(3,4-difluorobenzoyl)-2,3-dihydro-1H-imidazo[2,1-a]isoindol-5(9bH)-one (ML375).
    Gentry PR; Kokubo M; Bridges TM; Kett NR; Harp JM; Cho HP; Smith E; Chase P; Hodder PS; Niswender CM; Daniels JS; Conn PJ; Wood MR; Lindsley CW
    J Med Chem; 2013 Nov; 56(22):9351-5. PubMed ID: 24164599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Further optimization of the M5 NAM MLPCN probe ML375: tactics and challenges.
    Kurata H; Gentry PR; Kokubo M; Cho HP; Bridges TM; Niswender CM; Byers FW; Wood MR; Daniels JS; Conn PJ; Lindsley CW
    Bioorg Med Chem Lett; 2015 Feb; 25(3):690-4. PubMed ID: 25542588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Mechanisms of Action of M5 Muscarinic Acetylcholine Receptor Allosteric Modulators.
    Berizzi AE; Gentry PR; Rueda P; Den Hoedt S; Sexton PM; Langmead CJ; Christopoulos A
    Mol Pharmacol; 2016 Oct; 90(4):427-36. PubMed ID: 27461343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a highly potent, novel M5 positive allosteric modulator (PAM) demonstrating CNS exposure: 1-((1H-indazol-5-yl)sulfoneyl)-N-ethyl-N-(2-(trifluoromethyl)benzyl)piperidine-4-carboxamide (ML380).
    Gentry PR; Kokubo M; Bridges TM; Noetzel MJ; Cho HP; Lamsal A; Smith E; Chase P; Hodder PS; Niswender CM; Daniels JS; Conn PJ; Lindsley CW; Wood MR
    J Med Chem; 2014 Sep; 57(18):7804-10. PubMed ID: 25147929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery, synthesis and characterization of a highly muscarinic acetylcholine receptor (mAChR)-selective M5-orthosteric antagonist, VU0488130 (ML381): a novel molecular probe.
    Gentry PR; Kokubo M; Bridges TM; Cho HP; Smith E; Chase P; Hodder PS; Utley TJ; Rajapakse A; Byers F; Niswender CM; Morrison RD; Daniels JS; Wood MR; Conn PJ; Lindsley CW
    ChemMedChem; 2014 Aug; 9(8):1677-82. PubMed ID: 24692176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of the first highly M5-preferring muscarinic acetylcholine receptor ligand, an M5 positive allosteric modulator derived from a series of 5-trifluoromethoxy N-benzyl isatins.
    Bridges TM; Marlo JE; Niswender CM; Jones CK; Jadhav SB; Gentry PR; Plumley HC; Weaver CD; Conn PJ; Lindsley CW
    J Med Chem; 2009 Jun; 52(11):3445-8. PubMed ID: 19438238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute Negative Allosteric Modulation of M
    Gould RW; Gunter BW; Bubser M; Matthews RT; Teal LB; Ragland MG; Bridges TM; Garrison AT; Winder DG; Lindsley CW; Jones CK
    ACS Chem Neurosci; 2019 Aug; 10(8):3740-3750. PubMed ID: 31268669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a Novel Allosteric Site at the M
    Burger WAC; Gentry PR; Berizzi AE; Vuckovic Z; van der Westhuizen ET; Thompson G; Yeasmin M; Lindsley CW; Sexton PM; Langmead CJ; Tobin AB; Christopoulos A; Valant C; Thal DM
    ACS Chem Neurosci; 2021 Aug; 12(16):3112-3123. PubMed ID: 34351123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continued optimization of the M
    McGowan KM; Nance KD; Cho HP; Bridges TM; Conn PJ; Jones CK; Lindsley CW
    Bioorg Med Chem Lett; 2017 Mar; 27(6):1356-1359. PubMed ID: 28237763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemical lead optimization of a pan G(q) mAChR M(1), M(3), M(5) positive allosteric modulator (PAM) lead. Part I: Development of the first highly selective M(5) PAM.
    Bridges TM; Kennedy JP; Cho HP; Breininger ML; Gentry PR; Hopkins CR; Conn PJ; Lindsley CW
    Bioorg Med Chem Lett; 2010 Jan; 20(2):558-62. PubMed ID: 20004578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective inhibition of M
    Gunter BW; Gould RW; Bubser M; McGowan KM; Lindsley CW; Jones CK
    Addict Biol; 2018 Sep; 23(5):1106-1116. PubMed ID: 29044937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and Optimization of Potent and CNS Penetrant M
    Bender AM; Cho HP; Nance KD; Lingenfelter KS; Luscombe VB; Gentry PR; Voigtritter K; Berizzi AE; Sexton PM; Langmead CJ; Christopoulos A; Locuson CW; Bridges TM; Chang S; O'Neill JC; Zhan X; Niswender CM; Jones CK; Conn PJ; Lindsley CW
    ACS Chem Neurosci; 2018 Jul; 9(7):1572-1581. PubMed ID: 29678111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of (R)-(2-fluoro-4-((-4-methoxyphenyl)ethynyl)phenyl) (3-hydroxypiperidin-1-yl)methanone (ML337), an mGlu3 selective and CNS penetrant negative allosteric modulator (NAM).
    Wenthur CJ; Morrison R; Felts AS; Smith KA; Engers JL; Byers FW; Daniels JS; Emmitte KA; Conn PJ; Lindsley CW
    J Med Chem; 2013 Jun; 56(12):5208-12. PubMed ID: 23718281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Muscarinic M
    Berizzi AE; Perry CJ; Shackleford DM; Lindsley CW; Jones CK; Chen NA; Sexton PM; Christopoulos A; Langmead CJ; Lawrence AJ
    Neuropsychopharmacology; 2018 Jun; 43(7):1510-1517. PubMed ID: 29483658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of N-(4-methoxy-7-methylbenzo[d]thiazol-2-yl)isonicatinamide, ML293, as a novel, selective and brain penetrant positive allosteric modulator of the muscarinic 4 (M4) receptor.
    Salovich JM; Vinson PN; Sheffler DJ; Lamsal A; Utley TJ; Blobaum AL; Bridges TM; Le U; Jones CK; Wood MR; Daniels JS; Conn PJ; Niswender CM; Lindsley CW; Hopkins CR
    Bioorg Med Chem Lett; 2012 Aug; 22(15):5084-8. PubMed ID: 22738637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and Synthesis of Clinical Candidate PF-06852231 (CVL-231): A Brain Penetrant, Selective, Positive Allosteric Modulator of the M
    Butler CR; Popiolek M; McAllister LA; LaChapelle EA; Kramer M; Beck EM; Mente S; Brodney MA; Brown M; Gilbert A; Helal C; Ogilvie K; Starr J; Uccello D; Grimwood S; Edgerton J; Garst-Orozco J; Kozak R; Lotarski S; Rossi A; Smith D; O'Connor R; Lazzaro J; Steppan C; Steyn SJ
    J Med Chem; 2024 Jul; 67(13):10831-10847. PubMed ID: 38888621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Muscarinic Acetylcholine Receptor M
    Bender AM; Garrison AT; Lindsley CW
    ACS Chem Neurosci; 2019 Mar; 10(3):1025-1034. PubMed ID: 30280567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. M5 receptor activation produces opposing physiological outcomes in dopamine neurons depending on the receptor's location.
    Foster DJ; Gentry PR; Lizardi-Ortiz JE; Bridges TM; Wood MR; Niswender CM; Sulzer D; Lindsley CW; Xiang Z; Conn PJ
    J Neurosci; 2014 Feb; 34(9):3253-62. PubMed ID: 24573284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel allosteric effects of amiodarone at the muscarinic M5 receptor.
    Stahl E; Ellis J
    J Pharmacol Exp Ther; 2010 Jul; 334(1):214-22. PubMed ID: 20348203
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.